Acquired amegakaryocytic thrombocytopenia (AAT), a rare entity characterized by severe thrombocytopenia and the absence of megakaryocytes in the bone marrow, may mimic or precede the diagnosis of aplastic anemia (AA). Here, we describe a patient who presented with apparent Epstein-Barr virus (EBV)-associated immune thrombocytopenia resistant to several lines of therapies, which was in fact a form of AAT with some features of AA. He eventually responded to therapy with eltrombopag, cyclosporine A (CSA), and antithymocyte globulin (ATG) and recovered completely. EBV infection is known to cause a variety of benign and malignant hematologic disorders, including bone marrow failure. However, to the best of our knowledge, this is the first case report of EBV-associated AAT. Treatment options for AAT are still not well defined, and even response to eltrombopag together with CSA and ATG does not always imply successful therapy. The natural history of EBV infection may well be sufficient to explain unexpected eventual recovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000484595 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fetal Intracranial Hemorrhage due to Uniparental Disomy and Unmasked MPL-Related Congenital Amegakaryocytic Thrombocytopenia.
Prenat Diagn
December 2024
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia.
Ann Hematol
December 2024
Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Recombinant human thrombopoietin (rhTPO) is commonly used to improve low platelet status in immune thrombocytopenia (ITP), as one protein product, even with a very low rate, there is still the possibility to produce neutralizing antibodies of thrombopoietin (TPO). We described a 7-year-old boy with ITP and normal TPO levels who had previously received rhTPO for 2 weeks but showed persistent thrombocytopenia and was misdiagnosed as acquired amegakaryocytic thrombocytopenia (AATP) and ineffectively treated with cyclosporine A (CsA) in combination with avatrombopag (AVA). As suspicious the TPO neutralizing antibody development as re-test of TPO level is 0, the CD20 + deletion antibody drug rituximab (RTX) was prescribed and received efficacy.
View Article and Find Full Text PDFA Rare THPO Gene Mutation in a Saudi Female Child: A Case Report and Literature Review.
Cureus
September 2024
Pediatrics Genetics, Armed Forces Hospital Southern Region, Khamis Mushait, SAU.
Thrombopoietin (THPO) is a regulator of megakaryopoiesis and thrombopoiesis. Mutation of the gene is known to cause congenital amegakaryocytic thrombocytopenia (CAMT2), which is a rare inherited disorder characterized by early infancy thrombocytopenia and absent or decreased megakaryocytes with gradual progression to pancytopenia. We report the case of a Saudi girl who had been asymptomatic until age seven when she was found to have unexplained thrombocytopenia.
View Article and Find Full Text PDFManagement of Acquired Amegakaryocytic Thrombocytopenia and Severe Coronary Artery Disease.
Eur J Case Rep Intern Med
September 2024
Department of Internal Medicine, University of New Mexico, Albuquerque, USA.
Article Synopsis
- - Amegakaryocytic thrombocytopenia is a rare blood disorder that severely reduces platelet production due to a lack of megakaryocytes, which can lead to serious complications, especially in patients with cardiovascular issues.
- - A case study presented a patient with chest pain diagnosed with NSTEMI, who also had severe thrombocytopenia and triple vessel disease, complicating urgent surgical options despite treatment efforts.
- - Effective management requires accurate diagnosis to differentiate amegakaryocytic thrombocytopenia from immune thrombocytopenia and emphasizes the need for interdisciplinary collaboration in treating complex cases in modern healthcare.
Acquired Amegakaryocytic Thrombocytopenia with Glycoprotein IIb/IIIa Antibody in a Patient with Mantle Cell Lymphoma.
Intern Med
September 2024
Department of Hematology, Nagano Red Cross Hospital, Japan.
Background Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare disorder characterized by thrombocytopenia, marked megakaryocytic hypoplasia, and preserved other-lineage hematopoiesis in the bone marrow. The etiology of AAMT remains poorly understood owing to its rarity. Case description We encountered a diagnostically challenging case involving a 66-year-old man who showed severe thrombocytopenic bleeding with isolated megakaryocytic hypoplasia, elevated serum thrombopoietin levels, glycoprotein IIb/IIIa antibody positivity, and prolonged platelet transfusion refractoriness following mantle cell lymphoma (MCL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!